Stifel Nicolaus Downgrades Fulcrum Therapeutics (NASDAQ:FULC) to Hold

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Briefing.com reports.

A number of other equities research analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, August 1st. Bank of America raised shares of Fulcrum Therapeutics from an “underperform” rating to a “neutral” rating and increased their price objective for the company from $5.00 to $10.00 in a research report on Monday. Finally, Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $14.29.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock traded down $5.41 during mid-day trading on Thursday, reaching $3.44. 20,655,682 shares of the company traded hands, compared to its average volume of 839,495. The firm’s 50 day moving average price is $8.52 and its 200 day moving average price is $8.36. The firm has a market capitalization of $213.81 million, a price-to-earnings ratio of -2.15 and a beta of 2.23. Fulcrum Therapeutics has a 52-week low of $2.88 and a 52-week high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. The company had revenue of $80.00 million during the quarter, compared to analysts’ expectations of $80.00 million. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. During the same quarter last year, the business posted ($0.38) EPS. On average, sell-side analysts anticipate that Fulcrum Therapeutics will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in FULC. Capstone Investment Advisors LLC bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at $68,000. Affinity Asset Advisors LLC purchased a new position in Fulcrum Therapeutics in the fourth quarter worth about $844,000. Vestal Point Capital LP bought a new stake in Fulcrum Therapeutics during the fourth quarter worth approximately $6,919,000. ADAR1 Capital Management LLC purchased a new stake in Fulcrum Therapeutics during the fourth quarter valued at approximately $4,302,000. Finally, Opaleye Management Inc. bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at approximately $878,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.